Therefore, many clinical trials addressed targeting EGFR using tyrosine kinase inhibitors or antibodies as monotherapy in ovarian cancer, although the results of these trials demonstrated no difference in survival [126]. The gene discussed is EGFR; the disease is ovarian carcinoma.